AbbVie Seeks FDA Approval for Tavapadon for Treating…

AbbVie has recently submitted a New Drug Application to the U.S. Food and Drug Administration for tavapadon intended for the treatment of Parkinson’s disease. Tavapadon, a selective dopamine D1/D5 receptor partial agonist, exhibited symptomatic improvements in patients across the Parkinson’s disease spectrum during Phase 3 trials, further establishing its potential as a treatment option for Parkinson’s disease.

The pivotal TEMPO clinical development program formed the basis for this NDA submission, encompassing two Phase 3 trials (TEMPO-1 and TEMPO-2) that focused on early Parkinson’s disease and one Phase 3 trial (TEMPO-3) examining tavapadon as an adjunct to levodopa in patients with motor fluctuations. Results from these trials demonstrated significant improvements in patients’ Movement Disorder Society – Unified Parkinson’s Disease Rating Scale, indicating enhanced efficacy and tolerability for tavapadon. Moreover, an ongoing open-label extension study (TEMPO-4) aims to evaluate the long-term clinical benefits of tavapadon.

Dr. Roopal Thakkar, Executive Vice President of R&D and Chief Scientific Officer at AbbVie, emphasized the importance of providing innovative treatment options for those living with Parkinson’s disease. Acknowledging the limitations of existing oral treatments, AbbVie is dedicated to offering advanced solutions to enhance motor control and quality of life for individuals affected by this challenging condition.

The TEMPO Clinical Development Program, supported by results from three placebo-controlled studies, highlights the efficacy and safety profiles of tavapadon across different patient populations. TEMPO-1 and TEMPO-2 focused on patients with early Parkinson’s disease, while TEMPO-3 examined the use of tavapadon as an adjunct to levodopa in patients experiencing motor fluctuations. The ongoing TEMPO-4 study aims to assess the long-term safety and efficacy of tavapadon over 58 weeks of treatment.

In TEMPO-1, patients with early Parkinson’s disease were enrolled in a 27-week trial assessing the efficacy of two fixed doses of tavapadon. Similarly, TEMPO-2 examined the use of flexible doses of tavapadon in early Parkinson’s disease, showcasing promising results in improving patients’ disease severity and quality of life. Finally, TEMPO-3 focused on evaluating tavapadon as an adjunct therapy to levodopa for advanced Parkinson’s disease, demonstrating improvements in motor function and overall disease management.

Overall, the results from the TEMPO trials indicated that tavapadon was well-tolerated, with the majority of adverse events being non-serious and mild or moderate in severity. The occurrence of serious adverse events and deaths was low and comparable between the placebo and tavapadon groups, emphasizing the safety profile of this novel treatment option for Parkinson’s disease. With the potential approval of tavapadon, AbbVie aims to enhance its leadership in Parkinson’s disease management by offering patients a once-daily oral treatment option that addresses the unmet needs of individuals living with this condition.